Clinical Trial Update: Telisotuzumab Vedotin and Osimertinib for the Treatment of Progressive, Incurable, Non Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for telisotuzumab vedotin in combination with osimertinib for progressive non-small cell lung cancer, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Osimertinib (osimertinib)
• Telisotuzumab Vedotin (Telisotuzumab Vedotin)

Snippet

Sponsor: Jonsson Comprehensive Cancer Center | Conditions: Lung Non-Small Cell Carcinoma | Phase 2 | Status: RECRUITING